Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) EPS (Weighted Average and Diluted) (2020 - 2025)

Viridian Therapeutics, Inc.\DE has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$73.84 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$73.84 for Q4 2025, down 150.06% from a year ago — trailing twelve months through Dec 2025 was -$164.66 (down 6332.03% YoY), and the annual figure for FY2025 was -$221.65, down 7119.87%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$73.84 at Viridian Therapeutics, Inc.\DE, down from -$22.96 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for VRDN hit a ceiling of $147.51 in Q4 2024 and a floor of -$177.97 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.44 (2023), compared with a mean of -$17.95.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 24966.2% in 2022 and later skyrocketed 245750.0% in 2024.
  • Viridian Therapeutics, Inc.\DE's EPS (Weighted Average and Diluted) stood at -$0.71 in 2021, then tumbled by 24966.2% to -$177.97 in 2022, then surged by 100.03% to $0.06 in 2023, then skyrocketed by 245750.0% to $147.51 in 2024, then plummeted by 150.06% to -$73.84 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$73.84 (Q4 2025), -$22.96 (Q3 2025), and -$66.99 (Q2 2025) per Business Quant data.